Wyss InstituteVaccines – Wyss Institute

Kwasi Adu-Berchie named 2024 STAT Wunderkind

Jessica Leff — Wed, 16 Oct 2024 14:11:12 +0000

By Lindsay Brownell (BOSTON) – The Wyss Institute is thrilled to announce that Kwasi Adu-Berchie, Ph.D., a member of the Wyss’ Advanced Technology Team working in Immuno-Materials Platform led by Core Faculty member Dave Mooney, Ph.D., has been named a 2024 STAT Wunderkind by STAT News. The Wunderkinds awards are given annually by STAT News to the next generation of scientific superstars who…

Source

DoriNano – Improved DNA Origami Nanodelivery to Fight Cancer and Other Diseases

Jessica Leff — Fri, 04 Oct 2024 18:20:45 +0000

We’re developing DNA Origami nanodelivery, which is transforming nanoparticle industry. Developed at the Dana Farber Cancer Institute and the Wyss Institute at Harvard University, this innovative approach overcomes the challenges of other nanoparticles, offering stability, high drug loading capacity, nano-scale control of cargo spacing, and more – making it a highly customizable solution for…

Source

Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies

Jessica Leff — Wed, 02 Oct 2024 13:20:13 +0000

By Benjamin Boettner (BOSTON) — Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Attivare Therapeutics Inc. announced that Attivare has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences (SEAS)…

Source

Boosting CAR-T cell therapies from under the skin

Jessica Leff — Wed, 12 Jun 2024 13:15:07 +0000

By Benjamin Boettner (BOSTON) — CAR-T cell therapies are transforming the treatment of previously incurable blood cancers. Six approved CAR-T products have been administered to more than 20,000 people, and more than 500 clinical trials are underway. However, according to a recent study out of the Massachusetts General Hospital, among 100 patients suffering from lymphomas, myelomas or B-cell…

Source

Expanding a lymph node, boosting a vaccine

Jessica Leff — Mon, 06 May 2024 09:15:39 +0000

By Benjamin Boettner (BOSTON) — Each one of us has around 600 lymph nodes (LNs) – small, bean-shaped organs that house various types of blood cells and filter lymph fluid – scattered throughout our bodies. Many of us have also experienced some of our LNs to temporarily swelling during infections with viruses or other pathogens. This LN expansion and subsequent contraction can also result from…

Source

DoriVac: DNA Origami-Based Vaccines for Combination Immunotherapy

Jessica Leff — Wed, 01 May 2024 17:54:19 +0000

Serious diseases like cancer and autoimmune conditions require multiple drugs to treat and manage them, but combining drugs is challenging for a number of reasons. The primary problem is toxicity, as the side effects of multiple drugs can compound each other and produce much greater patient suffering than either drug alone – sometimes to the point that the combination is too dangerous to give to a…

Source

Cellular “Backpacks” to Fight Cancer, Autoimmune Disorders, and More

admin — Tue, 30 Apr 2024 20:33:51 +0000

Macrophages are the body’s multipurpose defense agents, patrolling for pathogens and engulfing cellular debris, foreign substances, microbes, and even cancer cells. But cancerous tumors have evolved an insidious defense mechanism: they can switch arriving macrophages from an active, pro-inflammatory state to a passive, anti-inflammatory state, in which they actually promote the tumor’s growth.

Source

DNA origami-based vaccines toward safe and highly-effective precision cancer immunotherapy

Jessica Leff — Fri, 15 Mar 2024 11:00:37 +0000

By Benjamin Boettner (BOSTON) — Therapeutic cancer vaccines are a form of immunotherapy in the making that could not only destroy cancer cells in patients, but keep a cancer from coming back and spreading. Multiple therapeutic cancer vaccines are being studied in clinical trials, but despite their promise, they are not routinely used yet by clinical oncologists to treat their patients.

Source

Changing the calculus of cancer treatment

Jessica Leff — Wed, 24 Jan 2024 22:04:52 +0000

This year’s American Cancer Society’s cancer statistics report revealed that despite falling rates of some cancers over the last few decades, the incidence of breast, prostate, oral cavity, melanoma, and kidney cancers has been rising in recent years. Most concerningly, colorectal cancer has jumped to become the leading cause of cancer deaths in adults under 50. Despite the strides made by new…

Source

Biomaterial-delivered one-two punch boosts cancer immunotherapy

Jessica Leff — Thu, 13 Jul 2023 14:50:15 +0000

By Benjamin Boettner (BOSTON) — Cancer immunotherapy has brought major improvement in patient survival and quality of life, especially with the success of adoptive T cell and immune checkpoint inhibitor therapies. Unfortunately, in contrast to different blood cancers, the effectiveness of adoptive T cell therapies in the treatment of solid tumors, which comprise about 90% of all tumors…

Source